
Commentary|Articles|May 14, 2015
- NSCLC (Issue 7)
- Volume 7
- Issue 2
MET as a Secondary Driver in Lung Cancer
Author(s)D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET as a secondary driver in lung cancer.
Advertisement
D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET as a secondary driver in lung cancer.
<<<
View more from the NSCLC Special Report
Articles in this issue
over 10 years ago
MiR-34a Link to PD-L1 May Mean New Immunotherapy in NSCLCover 10 years ago
More Endpoints Not Necessarily Merrier in NSCLC Drug Trialsover 10 years ago
Combining Bevacizumab With EGFR TKIs in Lung Cancerover 10 years ago
Characteristics of Additional KRAS Subsets in Lung Cancerover 10 years ago
US-Cuban Partnership Developing Anticancer Vaccine for NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Dr Hans Lee on the Game-Changing Myeloma Research From ASH 2025
3
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
4
The Targeted Pulse: Blood and Breast Cancer News
5








































